Ifosfamide + mitoxantrone in advanced breast cancer previously treated with anthracyclines.
We treated 19 patients previously exposed to anthracyclines (progression during therapy or after discontinuation of therapy) with ifosfamide (IFO) 2 g/m2 i.v. in a 1-h infusion daily for 3 days with mesna uroprotection and mitoxantrone (MZT) 12 mg/m2 on day 1 of every 3-week cycle. The response rate was assessed after two cycles. A response to treatment was observed in 6 of 15 evaluable patients (40%), with no complete remission and 6 partial remissions. The median duration of response was 6+ months (3+ to 12+). The toxicity was acceptable, with three episodes of grade 3-4 myelosuppression (8%) and one case of congestive heart failure resulting from a fluid overload that responded to medical treatment. The IFO-MZT combination is an effective second-line regimen in advanced breast cancer previously treated with anthracyclines.
Bellmunt
J
J
Department of Medical Oncology, Hospital Valle Hebron, Barcelona, Spain.
Morales
S
S
Navarro
M
M
Solé
L A
LA
D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy*; D004317:Doxorubicin / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D007069:Ifosfamide / Q000008:administration & dosage*; D008875:Middle Aged; D008942:Mitoxantrone / Q000008:administration & dosage*
D004317:Doxorubicin; D008942:Mitoxantrone; D007069:Ifosfamide